These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1098 related items for PubMed ID: 9641684

  • 21. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies.
    Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE.
    AIDS Res Hum Retroviruses; 2002 Nov 01; 18(16):1207-17. PubMed ID: 12487827
    [Abstract] [Full Text] [Related]

  • 22. Towards a structure of the HIV-1 envelope glycoprotein gp120: an immunochemical approach.
    Moore JP, Jameson BA, Sattentau QJ, Willey R, Sodroski J.
    Philos Trans R Soc Lond B Biol Sci; 1993 Oct 29; 342(1299):83-8. PubMed ID: 7904352
    [Abstract] [Full Text] [Related]

  • 23. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    Roben P, Moore JP, Thali M, Sodroski J, Barbas CF, Burton DR.
    J Virol; 1994 Aug 29; 68(8):4821-8. PubMed ID: 7518527
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.
    Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS.
    Proc Natl Acad Sci U S A; 2002 May 14; 99(10):6913-8. PubMed ID: 11997472
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. gp120: Biologic aspects of structural features.
    Poignard P, Saphire EO, Parren PW, Burton DR.
    Annu Rev Immunol; 2001 May 14; 19():253-74. PubMed ID: 11244037
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR, Weiss RA.
    Science; 2010 Aug 13; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes.
    Martin L, Stricher F, Missé D, Sironi F, Pugnière M, Barthe P, Prado-Gotor R, Freulon I, Magne X, Roumestand C, Ménez A, Lusso P, Veas F, Vita C.
    Nat Biotechnol; 2003 Jan 13; 21(1):71-6. PubMed ID: 12483221
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. B cell antigenic site mapping of HIV-1 glycoproteins.
    Neurath AR.
    Chem Immunol; 1993 Jan 13; 56():34-60. PubMed ID: 8452653
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The V3 domain of SIVmac251 gp120 contains a linear neutralizing epitope.
    Palker TJ, Muir AJ, Spragion DE, Staats HF, Langlois A, Montefiori DC.
    Virology; 1996 Oct 15; 224(2):415-26. PubMed ID: 8874502
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 55.